At a Press Meet on last Thursday after AGM, HPCL management has informed the
media that it has posted historic high net profit of Rs. 2733 crore for FY 14-15 and has
announced highest ever dividend of 245% (i.e. Rs. 24.50 per share). The company is going
ahead with JVs and expansion of its existing refinery capacities for which it has planned
capex of Rs. 45000 crore from current fiscal till 2020. Company is putting major thrust on
retail segment and has ambitious plans to have larger pie in the market share going forward
Cipla Ltd. (BSE Code: 500087) (CMP: Rs.654.95) (FV: Rs.2) (TGT: Rs.1500) Cipla Ltd is a pharmaceutical company with business units focused on Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company offers APIs, formulations and veterinary products. As of 31 March 2015, Cipla offered services across five continents and in countries like India, South Africa, Europe and North America, among others. It offers over 1,000 products across 120 countries that treat cardiovascular diseases, children’s health, dermatology and cosmetology, diabetes, Human Immunodeficiency Virus/Acquired Immuno Deficiency syndrome (HIV/AIDS), infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women’s health. It also offers veterinary products in categories such as companion, equine, general care, livestock and poultry. Cipla’s UK arm has entered into an agreement to acquire two US-based companies...

Comments
Post a Comment